AIDS TREATMENT NEWS - May 4, 2005
John S. James

Summary: The Institute of Medicine re-analyzed the key study that first showed prevention of mother-to-child HIV transmission by single-dose nevirapine. The IOM released a 150-page report concluding that the study was properly conducted and its results are valid.

Due to questions raised about HIVNET 012, the groundbreaking study that first showed that single-dose nevirapine could reduce transmission of HIV from infected mothers to their babies, the prestigious Institute of Medicine reviewed the study at the request of the U.S. National Institutes of Health, and presented an independent assessment. It concluded that the study was conducted ethically, that the findings that nevirapine is safe and effective for preventing maternal transmission were well supported, and that policy makers and scientists can rely on the resulting data and conclusions. [1, 2]

The IOM report will be published in a document of about 150 pages, including an executive summary of about 7 pages. Meanwhile, an uncorrected proof of the executive summary and complete report are available online. [2] A report of the press briefing of April 8 was published in Science, April 15. [3] AIDS Treatment News published a background report on the recent controversy last December. [4]

References

[1] Press release from the Institute of Medicine, April 7, 2005,
http://www.iom.edu/report.asp?id=26287 (click on "Press Release").

[2] Complete report, Review of the HIVNET 012 Perinatal HIV Prevention Study, http://books.nap.edu/catalog/11264.html

[3] For a report from the public press briefing of April 8, see Jennifer Couzin, "IOM Panel Clears HIV Prevention Study," Science. 2005 Apr 15;308(5720):334.

[4] "Nevirapine Misinformation: Will It Kill?" by John S. James. AIDS Treatment News, 2004 Dec. Reprinted in IAPAC Monthly, December 2004.

050504
ATN050505

Copyright © 2005 - by John S. James. See "Permission to Copy" at: http://www.aidsnews.org/canhelp. How to help AIDS Treatment News: http://www.aidsnews.org/canhelp.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .